The presence of these antibodies could define a rare subset of multiple sclerosis patients, as occurs in other neuroinflammatory pathologies; however, despite our work validates the initial description, the clinical and pathophysiological relevance of these autoantibodies in multiple sclerosis remains to be elucidated in autoantibody passive-transfer animal models, and larger prospective series are needed to characterize phenotypically anti-FLOT1/2 positive patients. This evidence concerns the gene FLOT1 and multiple sclerosis.